Baxter International has signed an agreement with Dorizoe Lifesciences, a contract research and development organization, for development of more than 20 generic injectable products, including anti-infectives, oncolytics, and cardiovascular medicines. Dorizoe will work with Baxter to perform certain product development activities, and Baxter will hold worldwide manufacturing and commercialization rights. Financial terms of the agreement were not disclosed.

Dorizoe provides services for pharmaceutical companies, including formulation development, analytical development, technology transfer and regulatory filing support.

Baxter recently announced plans to expand its presence in the generic injectables space with the pending acquisition of Claris Injectables. The acquisition of Claris, which is expected to close in the second half of 2017, will provide Baxter with a currently marketed portfolio of molecules in anesthesia and analgesics, renal, anti-infectives, and critical care in a variety of presentations including bags, vials, and ampoules along with pipeline and manufacturing capabilities. Baxter also recently announced a strategic partnership with ScinoPharma, a contract active pharmaceutical ingredient manufacturer, to develop, manufacture, and commercialize five generic injectables used in cancer treatment, with an option to add up to 15 additional injectable molecules.

Source: Baxter International